Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Node--Negative, p53--Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma.
Context.--Alterations in the tumor microenvironment affect the response to immunotherapy and are associated with clinical outcomes. However, the role of B7 family checkpoint molecules in pancreatic ductal adenocarcinoma (PDAC) remains unclear. Objective.--To investigate the expression of programmed...
| Published in: | Archives of Pathology & Laboratory Medicine Vol. 147; no. 4; pp. 465 - 474 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | pictorial research tables/charts Journal Article |
| Published: |
College of American Pathologists
Apr2023
|
| Online Access: | View this record in EBSCOhost |